Manufactures specialty pharmaceutical and fine chemical intermediates, including fluorinated and iodine-based compounds, for global drugmakers.
Manufactures specialty pharmaceutical and fine chemical intermediates, including fluorinated and iodine-based compounds, for global drugmakers.
In one line: A niche Indian pharma-intermediate chemical maker.
Moat: narrow (process know-how, regulatory licence). Specialized fluorination/iodination chemistry capability is not widely replicated by peers.
Headquarters: Ahmedabad, India · Employees: 1,713
Size Acutaas Chemicals (ACUTAAS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $3.50B, the 263rd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹3,991 on 18 Nov 2026.
Performance Over six months the shares gained 38.3%, against +8.1% for the median peer and +3.8% for the India market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 45.2% over the last twelve months (peer median +9.4%); the operating margin is 36.5% (peer median 12.2%).
Valuation It trades at 63.6× forward earnings against a peer median of 19.6× (2nd most expensive of 12).
Capital Return on invested capital runs 15.8 points above its cost of capital (9.9% WACC).
Next results Next results expected around 14 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹15.9B | ₹13.4B | ₹10.1B | ₹7.17B | ₹6.17B |
| Revenue growth | — | +33% | +40% | +16% | — |
| Gross profit | ₹7.68B | ₹5.31B | ₹2.73B | ₹1.58B | ₹1.60B |
| EBITDA | ₹6.23B | ₹4.84B | ₹2.34B | ₹1.30B | ₹1.25B |
| Net income | ₹4.39B | ₹3.56B | ₹1.59B | ₹428M | ₹833M |
| Free cash flow | n/a | -₹285M | -₹717M | -₹1.93B | -₹311M |
| Capital expenditure | n/a | ₹3.28B | ₹1.95B | ₹3.15B | ₹964M |
| Total debt | ₹151M | ₹356M | ₹129M | ₹2.17B | ₹36.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Acutaas Chemicals ACUTAAS.NS | $3.50B | +38% | +45% | 36% | 63.6× | n/a |
| Navin Fluorine International NAVINFLUOR.NS | $5.66B | +45% | +46% | 30% | 51.6× | 37.0% |
| Srf SRF.NS | $7.77B | -7% | +20% | 19% | 30.0× | 25.5% |
| Neogen Chemicals NEOGEN.NS | $893M | +76% | +27% | 14% | 123.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ACUTAAS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +22.7% | +2.6% | 4th highest of 21 |
| 6-month return | +38.3% | +8.1% | 4th highest of 20 |
| Distance from 52-week high | -3.4% | -23.4% | 2nd highest of 21 |
| Revenue growth (TTM) | +45.2% | +9.4% | 4th highest of 18 |
| Operating margin | 36.5% | 12.2% | highest of 16 |
| Forward P/E | 63.6× | 19.6× | 2nd most expensive of 12 |
| ROIC minus cost of capital | +15.8 pp | +3.7 pp | 2nd highest of 16 |
| EV / EBITDA | 52.1× | 14.5× | 2nd most expensive of 9 |
| Net debt / EBITDA | -0.5× | 2.4× | 3rd least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $3.49B | -38% | +36% | -14% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 16.8× | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | n/a | 58.0% | +4.2% |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% | +7.8% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 11.3× | -7.0% | +2.0% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | n/a | 34.7% | +159.5% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 21.9× | 1.2% | +12.1% |